Antibody fragment (Fc) 2

[{"image":"https://icons.cdn.biorender.com/w75xh75/6679aef1666b6a652f957369/6679aec6666b6a652f9572ec.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/6679aef1666b6a652f957369/6679aec6666b6a652f9572ec.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/6679aef1666b6a652f95736a/6679aec6666b6a652f9572ec.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/6679aef1666b6a652f95736a/6679aec6666b6a652f9572ec.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/6679aef1666b6a652f95736b/6679aec6666b6a652f9572ec.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/6679aef1666b6a652f95736b/6679aec6666b6a652f9572ec.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/6679aef1666b6a652f95736c/6679aec6666b6a652f9572ec.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/6679aef1666b6a652f95736c/6679aec6666b6a652f9572ec.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/6679aef1666b6a652f95736d/6679aec6666b6a652f9572ec.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/6679aef1666b6a652f95736d/6679aec6666b6a652f9572ec.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/6679aef1666b6a652f95736e/6679aec6666b6a652f9572ec.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/6679aef1666b6a652f95736e/6679aec6666b6a652f9572ec.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/6679aef1666b6a652f95736f/6679aec6666b6a652f9572ec.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/6679aef1666b6a652f95736f/6679aec6666b6a652f9572ec.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/6679aef1666b6a652f957370/6679aec6666b6a652f9572ec.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/6679aef1666b6a652f957370/6679aec6666b6a652f9572ec.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/6679aef1666b6a652f957371/6679aec6666b6a652f9572ec.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/6679aef1666b6a652f957371/6679aec6666b6a652f9572ec.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/6679aef1666b6a652f957372/6679aec6666b6a652f9572ec.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/6679aef1666b6a652f957372/6679aec6666b6a652f9572ec.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/6679aef1666b6a652f957373/6679aec6666b6a652f9572ec.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/6679aef1666b6a652f957373/6679aec6666b6a652f9572ec.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/6679aef1666b6a652f957374/6679aec6666b6a652f9572ec.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/6679aef1666b6a652f957374/6679aec6666b6a652f9572ec.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/6679aef1666b6a652f957375/6679aec6666b6a652f9572ec.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/6679aef1666b6a652f957375/6679aec6666b6a652f9572ec.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/6679aef1666b6a652f957376/6679aec6666b6a652f9572ec.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/6679aef1666b6a652f957376/6679aec6666b6a652f9572ec.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/6679aef1666b6a652f957377/6679aec6666b6a652f9572ec.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/6679aef1666b6a652f957377/6679aec6666b6a652f9572ec.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/6679aef1666b6a652f957378/6679aec6666b6a652f9572ec.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/6679aef1666b6a652f957378/6679aec6666b6a652f9572ec.png"}]